[Pharmacokinetic and pharmacodynamic features of hypertensive drugs in treatment of patients with arterial hypertension associated with liver disease].
OBJECTIVE
Being based on pharmacokinetic and pharmacodynamic property of inhibitor ACE and -adrenoblokers to optimise treatment of patients arterial hypertension (AH), a liver proceeding against chronic diseases.


METHODS
In research it is included 360 patients with AH 2 degree in a combination with steatosis and the cirrhosis of liver of an alcoholic etiology of a class A by Chald-Pugh. In control group patients with stomach ulcer are included in stages of remission with normal function of a liver. For the purpose of diagnostics AH and an efficiency estimation hypotensive preparations the patient it is spent systolic arterial pressure. For a pharmacokinetics estimation definition of concentration of preparations in whey of blood sick of a method of a highly effective liquid chromatography was spent.


RESULTS
At patients AH with the normal and broken function of a liver after reception lizinoprili and atonololi it is noted distinctions in pharmacokinetic parametres. The broken function of a liver at patients AH against the cirrhosis lover is at the bottom of changes pharmacokinetic parametres metoprololi and enalaprili.
Mikheeva
O M
OM
D000319:Adrenergic beta-Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005234:Fatty Liver / Q000150:complications* / Q000378:metabolism; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D008103:Liver Cirrhosis / Q000150:complications* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents